Anderson G W, Leary S E, Williamson E D, Titball R W, Welkos S L, Worsham P L, Friedlander A M
United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702-5011, USA.
Infect Immun. 1996 Nov;64(11):4580-5. doi: 10.1128/iai.64.11.4580-4585.1996.
The purified recombinant V antigen from Yersinia pestis, expressed in Escherichia coli and adsorbed to aluminum hydroxide, an adjuvant approved for human use, was used to immunize outbred Hsd:ND4 mice subcutaneously. Immunization protected mice from lethal bubonic and pneumonic plague caused by CO92, a wild-type F1+ strain, or by the isogenic F1- strain C12. This work demonstrates that a subunit plague vaccine formulated for human use provides significant protection against bubonic plague caused by an F1- strain (C12) or against substantial aerosol challenges from either F1+ (CO92) or F1-(C12) Y. pestis.
从鼠疫耶尔森菌中纯化的重组V抗原,在大肠杆菌中表达并吸附于氢氧化铝(一种已获批准用于人类的佐剂),用于对远交系Hsd:ND4小鼠进行皮下免疫。免疫可保护小鼠免受由野生型F1 +菌株CO92或同基因F1 -菌株C12引起的致死性腺鼠疫和肺鼠疫。这项研究表明,一种为人类使用而配制的亚单位鼠疫疫苗可提供显著保护,预防由F1 -菌株(C12)引起的腺鼠疫,或预防来自F1 +(CO92)或F1 -(C12)鼠疫耶尔森菌的大量气溶胶攻击。